InvestSMART

Telix Pharmaceuticals Limited (ASX: TLX) - Announcements

Current share price for TLX : $13.015 0.065 (0.50%)+

ASX company news and announcements for Telix Pharmaceuticals Limited (TLX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Telix Pharmaceuticals Limited (TLX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Telix Pharmaceuticals Limited (TLX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Telix Pharmaceuticals Limited (TLX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$4,429 Becoming a substantial holder 17 Nov 2025 8:17AM $14.130 $13.015 fallen by 7.89%
$4,429 Appendix 3Y Change in Director Interests - C Behrenbruch 7 Nov 2025 8:25AM $15.160 $13.015 fallen by 14.15%
$4,429 Application for quotation of securities - TLX 7 Nov 2025 8:25AM $15.160 $13.015 fallen by 14.15%
$4,429 Pending Release of Shares from Voluntary Escrow 29 Oct 2025 8:23AM $16.430 $13.015 fallen by 20.79%
$4,429 Cleansing Notice 29 Oct 2025 8:22AM $16.430 $13.015 fallen by 20.79%
$4,429 Application for quotation of securities - TLX 29 Oct 2025 8:22AM $16.430 $13.015 fallen by 20.79%
$4,429 Pending Release of Shares from Voluntary Escrow 24 Oct 2025 8:26AM $16.800 $13.015 fallen by 22.53%
$4,429 Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded 14 Oct 2025 4:31PM $14.360 $13.015 fallen by 9.37%
$4,429 Notification of cessation of securities - TLX 10 Oct 2025 8:33AM $15.410 $13.015 fallen by 15.54%
$4,429 Notification regarding unquoted securities - TLX 10 Oct 2025 8:33AM $15.410 $13.015 fallen by 15.54%
$4,429 Application for quotation of securities - TLX 10 Oct 2025 8:31AM $15.410 $13.015 fallen by 15.54%
$4,429 Change in substantial holding 8 Oct 2025 4:40PM $15.410 $13.015 fallen by 15.54%
$4,429 Becoming a substantial holder from CGF 25 Sep 2025 4:26PM $15.380 $13.015 fallen by 15.38%
$4,429 CMS Grants Transitional Pass-Through Status for Gozellix 23 Sep 2025 9:37AM $15.000 $13.015 fallen by 13.23%
$4,429 Ceasing to be a substantial holder from CGF 12 Sep 2025 4:52PM $13.690 $13.015 fallen by 4.93%
$4,429 Telix and FDA Agree Resubmission Pathway for Pixclara NDA 9 Sep 2025 8:32AM $13.600 $13.015 fallen by 4.30%
$4,429 Becoming a substantial holder from CGF 5 Sep 2025 4:35PM $13.800 $13.015 fallen by 5.69%
$4,429 Application for quotation of securities - TLX 5 Sep 2025 8:24AM $13.770 $13.015 fallen by 5.48%
$4,429 Pending Release of Shares from Voluntary Escrow 5 Sep 2025 8:24AM $13.770 $13.015 fallen by 5.48%
$4,429 Ceasing to be a substantial holder from CGF 1 Sep 2025 4:45PM $14.900 $13.015 fallen by 12.65%
$4,429 Telix Provides Regulatory Update on TLX250-CDx 28 Aug 2025 9:03AM $18.400 $13.015 fallen by 29.27%
$4,429 Becoming a substantial holder from CGF 25 Aug 2025 4:36PM $18.760 $13.015 fallen by 30.62%
$4,429 Telix H1 2025 Results Presentation 21 Aug 2025 8:29AM $16.920 $13.015 fallen by 23.08%
$4,429 Telix H1 2025 Results Presentation 21 Aug 2025 8:29AM $16.920 $13.015 fallen by 23.08%
$4,429 Telix H1 2025 Results Announcement 21 Aug 2025 8:28AM $16.920 $13.015 fallen by 23.08%

126 - 150 of 972 results

Page 6 of 39

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.